Exploring the Benefits of Continuous Treatment with Ozanimod for Relapsing Multiple Sclerosis Patients
As reported at the Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) forum by Jeffrey Cohen, MD, of the Cleveland Clinic in Ohio, patients with relapsing multiple sclerosis (RMS) showed stable or improved clinical and radiologic measures over 7 to 8 years of continuous treatment with ozanimod (Zeposia). Regardless of age category, the adjusted annualized relapse rate remained below 0.2, indicating positive outcomes for all patients.
Study Details
A total of 2,257 RMS patients from the parent SUNBEAM and RADIANCE trials participated in the DAYBREAK open-label extension study. Patients were categorized by age, with 118 individuals aged 25 or younger, 268 aged 26 to 35, 313 aged 36 to 50, and 62 aged 50 and older. Those continuously treated with 0.92 mg ozanimod consistently exhibited lower relapse rates compared to those who initially received interferon beta-1a before transitioning to ozanimod.
Age and Disease Activity
The data also revealed that patients who switched from interferon to ozanimod during the open-label extension caught up to those who were on ozanimod throughout the trials. Similarly, the number of gadolinium-enhancing lesions remained low across age groups, averaging 0.6 per scan. Additionally, the number of new or enlarging T2 lesions decreased with age, suggesting a potential decline in immune activity as patients got older.
Implications for Long-Term Treatment
Ozanimod, approved for RMS treatment in 2020, has shown promise in reducing relapse rates based on SUNBEAM and RADIANCE studies. The open-label extension study further demonstrated the sustained benefits of continuous ozanimod therapy. These results offer reassurance to clinicians treating older RMS patients with ozanimod, highlighting the potential for long-term disease stability and improvement.
Conclusion
The findings presented by Dr. Cohen shed light on the positive impact of continuous ozanimod treatment on RMS patients of all age groups. The data indicate a trend towards disease stability and improved outcomes, emphasizing the importance of early and continuous treatment with ozanimod in managing RMS. As research in this field progresses, clinicians can consider the benefits of long-term therapy with ozanimod to optimize patient care and enhance quality of life.